Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
The company will develop and produce premixes for human nutrition applications
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
The product basket increased to 1800 medicines and 285 Surgical Equipment
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
This innovative product eliminates two manufacturing steps and simplifies equipment setup
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
Subscribe To Our Newsletter & Stay Updated
